The written stability testing program is not followed.
See every finding in this document View the regulator's official sourceBy Category
Stability and storage Findings
in this category 1,333 findings drawn from 1,176 published documents. The most recent cases are below; the full set is in search.
See all Stability and storage findingsWhich agency cited it
Companies with the most findings
Recent findings
Procedures for the control of storage areas and stock rooms have not been adequately established.
See every finding in this document View the regulator's official sourceFailure to store stability samples in containers that simulate the market container.
See every finding in this document View the regulator's official sourceDrug product expiration dates are not related to the storage conditions stated on the labeling, as determined by stability studies.
See every finding in this document View the regulator's official sourceYour firm is not storing active pharmaceutical ingredients (API) per the labeled storage conditions.
See every finding in this document View the regulator's official sourceThe guidelines and/or procedures were inadequate in ensuring storage and/or transportation conditions would maintain the quality and safe distribution of the drug.
See every finding in this document View the regulator's official sourceNarrow by agency
Other categories
These findings are a record of the moment each document was published. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out — do not read them as the current state; check the regulator's official announcements for the latest status. Counts are measured from public data as of 2026-10-20, and findings are extracted automatically from the regulator's published documents. “View official source” on each case links directly to that document.
